3,837 Shares in Abbott Laboratories $ABT Acquired by Strathmore Capital Advisors Inc.

Key Points

• Strathmore Capital Advisors Inc. has acquired 3,837 shares of Abbott Laboratories, valued at approximately $511,000, marking a new stake during the second quarter.
• Research analysts have generally rated Abbott with a consensus of "Moderate Buy" and set an average price target of $144.47, with two analysts giving a Strong Buy rating.
• Abbott Laboratories reported an earnings per share (EPS) of $1.26 for the last quarter, meeting analyst expectations, while revenue increased by 7.4% year-over-year to $11.14 billion.

Strathmore Capital Advisors Inc. purchased a new position in shares of Abbott Laboratories (NYSE:ABT - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 3,837 shares of the healthcare product maker's stock, valued at approximately $511,000.

Several other hedge funds also recently added to or reduced their stakes in the stock. Kelly Financial Services LLC acquired a new position in shares of Abbott Laboratories during the first quarter valued at approximately $216,000. Bank Pictet & Cie Europe AG boosted its stake in shares of Abbott Laboratories by 1.9% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 152,719 shares of the healthcare product maker's stock valued at $17,274,000 after purchasing an additional 2,774 shares during the last quarter. Edge Financial Advisors LLC raised its holdings in Abbott Laboratories by 3.3% during the 1st quarter. Edge Financial Advisors LLC now owns 2,530 shares of the healthcare product maker's stock worth $336,000 after buying an additional 81 shares during the period. Public Employees Retirement System of Ohio bought a new position in shares of Abbott Laboratories in the fourth quarter valued at $84,418,000. Finally, SageView Advisory Group LLC boosted its position in Abbott Laboratories by 18.6% during the first quarter. SageView Advisory Group LLC now owns 18,294 shares of the healthcare product maker's stock worth $2,427,000 after purchasing an additional 2,873 shares during the period. 75.18% of the stock is owned by institutional investors and hedge funds.

Abbott Laboratories Trading Up 1.2%

Shares of ABT stock traded up $1.65 during trading hours on Friday, reaching $136.22. The company's stock had a trading volume of 11,531,874 shares, compared to its average volume of 4,828,819. The stock has a market capitalization of $237.09 billion, a P/E ratio of 17.07, a P/E/G ratio of 2.55 and a beta of 0.69. Abbott Laboratories has a one year low of $110.86 and a one year high of $141.23. The firm's fifty day simple moving average is $130.47 and its 200 day simple moving average is $131.19. The company has a current ratio of 1.82, a quick ratio of 1.30 and a debt-to-equity ratio of 0.25.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its quarterly earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $1.26. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The company had revenue of $11.14 billion for the quarter, compared to analysts' expectations of $11.01 billion. During the same quarter in the previous year, the business posted $1.14 EPS. Abbott Laboratories's revenue was up 7.4% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Equities research analysts expect that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 17th. Shareholders of record on Wednesday, October 15th will be paid a $0.59 dividend. The ex-dividend date is Wednesday, October 15th. This represents a $2.36 dividend on an annualized basis and a yield of 1.7%. Abbott Laboratories's dividend payout ratio (DPR) is presently 29.57%.

Insider Activity at Abbott Laboratories

In other news, CFO Philip P. Boudreau sold 5,550 shares of the firm's stock in a transaction on Friday, August 8th. The stock was sold at an average price of $134.55, for a total transaction of $746,752.50. Following the transaction, the chief financial officer owned 51,003 shares in the company, valued at approximately $6,862,453.65. This trade represents a 9.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 0.46% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on ABT. Leerink Partners initiated coverage on Abbott Laboratories in a research report on Monday, June 16th. They issued a "market perform" rating and a $143.00 target price on the stock. Leerink Partnrs raised Abbott Laboratories to a "hold" rating in a research report on Monday, June 16th. Morgan Stanley upped their price objective on Abbott Laboratories from $127.00 to $137.00 and gave the company an "equal weight" rating in a research note on Tuesday, July 15th. Evercore ISI increased their price target on Abbott Laboratories from $140.00 to $145.00 and gave the stock an "outperform" rating in a research note on Tuesday, July 8th. Finally, BTIG Research dropped their price objective on Abbott Laboratories from $148.00 to $145.00 and set a "buy" rating on the stock in a report on Friday, July 18th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $145.22.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.